Jennifer Ikle, MD, PhD (she/her/hers)

Ascendis Pharma, Inc
Palo Alto, California, United States

Disclosure information not submitted.

Presentation(s):

• SUN-201 - Safety and Effectiveness of Lonapegsomatropin in the Skybright Registry: Analysis of the First 100 Patients Enrolled with 2 Years of Follow-Up

  Sunday, June 14, 2026
  9:00 AM - 4:00 PM CT

• ORF47-06 - Navepegritide Combined with Lonapegsomatropin for the Treatment of Achondroplasia: An Open-Label Phase 2 Trial

  Monday, June 15, 2026
  2:30 PM - 2:45 PM CT